Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P02533: Variant p.Leu408Met

Keratin, type I cytoskeletal 14
Gene: KRT14
Feedback?
Variant information Variant position: help 408 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Leucine (L) to Methionine (M) at position 408 (L408M, p.Leu408Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In EBS1C. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 408 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 472 The length of the canonical sequence.
Location on the sequence: help RCEMEQQNQEYKILLDVKTR L EQEIATYRRLLEGEDAHLSS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         RCEMEQQNQEYKILLDVKTRLEQEIATYRRLLEGEDAHL------SS

Mouse                         RCEMEQQNQEYKILLDVKTRLEQEIATYRRLLEGEDAHLSS

Rat                           RCEMEQQNQEYKILLDVKTRLEQEIATYRRLLEGEDAHLSS

Chicken                       RCDMERQNHEYRVLLDVKCRLEQEIATYRRLLEGEDAHI--

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 472 Keratin, type I cytoskeletal 14
Domain 115 – 426 IF rod
Region 284 – 422 Coil 2
Helix 329 – 417



Literature citations
Mutation analysis of the entire keratin 5 and 14 genes in patients with epidermolysis bullosa simplex and identification of novel mutations.
Schuilenga-Hut P.H.L.; Vlies P.; Jonkman M.F.; Waanders E.; Buys C.H.C.M.; Scheffer H.;
Hum. Mutat. 21:447-447(2003)
Cited for: VARIANTS EBS1A PRO-130 AND GLN-419; VARIANT EBS1C MET-408; Mutations in KRT5 and KRT14 cause epidermolysis bullosa simplex in 75% of the patients.
Bolling M.C.; Lemmink H.H.; Jansen G.H.; Jonkman M.F.;
Br. J. Dermatol. 164:637-644(2011)
Cited for: VARIANTS EBS1C ASN-377; THR-377; CYS-388; MET-408; GLU-411 DEL AND PHE-412; VARIANTS EBS1A SER-123; CYS-125; PRO-130; ARG-272 AND GLN-419;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.